



Theratechnologies to present at the 27th Annual Canaccord Adams Global Growth Conference in Boston

Montréal, August 3rd, 2007 - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer of the Company, will present a corporate overview at the 27th Annual CanaccordAdams Global Growth Conference, which will take place next week at the InterContinental Boston. Mr. Rosconi will be speaking on Tuesday August 7th at 2:30 p.m.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is TH9507 now in a second confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

###

Contact:

Andrea Gilpin
Executive Director, IR & Communications
Theratechnologies Inc.
(514) 336-4804 x 205
communications@theratech.com